CNSX:CSI

(CSI) Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume63,715 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

(CSI) (CNSX:CSI) Vs. RIV, WLLW, LABS, KHRN, DN, and META

Should you be buying CSI stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to (CSI), including RIV Capital (RIV), Willow Biosciences Inc. (WLLW.TO) (WLLW), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), and Meta Growth (META).

RIV Capital (TSE:RIV) and (CSI) (CNSX:CSI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.

Profitability

This table compares RIV Capital and (CSI)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RIV CapitalN/AN/AN/A
(CSI)N/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for RIV Capital and (CSI), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RIV Capital01002.00
(CSI)0000N/A

RIV Capital currently has a consensus target price of C$4.00, suggesting a potential upside of 96.08%.

Valuation and Earnings

This table compares RIV Capital and (CSI)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RIV CapitalC$15.44 million18.49$-106,223,568.00C($0.76)-2.69
(CSI)N/AN/AN/AN/AN/A

(CSI) has lower revenue, but higher earnings than RIV Capital.

Summary

RIV Capital beats (CSI) on 1 of the 1 factors compared between the two stocks.

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and (CSI) (CNSX:CSI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Willow Biosciences Inc. (WLLW.TO) and (CSI)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)C$10,000.0015,778.30$-51,032,952.00C($0.41)-3.09
(CSI)N/AN/AN/AN/AN/A

(CSI) has lower revenue, but higher earnings than Willow Biosciences Inc. (WLLW.TO).

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and (CSI)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A
(CSI)N/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Willow Biosciences Inc. (WLLW.TO) and (CSI), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Willow Biosciences Inc. (WLLW.TO)0000N/A
(CSI)0000N/A

Willow Biosciences Inc. (WLLW.TO) currently has a consensus price target of C$2.25, suggesting a potential upside of 75.78%.

Summary

Willow Biosciences Inc. (WLLW.TO) beats (CSI) on 1 of the 1 factors compared between the two stocks.

(CSI) (CNSX:CSI) and MediPharm Labs (TSE:LABS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares (CSI) and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CSI)N/AN/AN/A
MediPharm LabsN/AN/AN/A

Valuation and Earnings

This table compares (CSI) and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CSI)N/AN/AN/AN/AN/A
MediPharm LabsC$36.01 million3.33C$-123,815,040.00C($0.48)-0.97

(CSI) has higher earnings, but lower revenue than MediPharm Labs.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for (CSI) and MediPharm Labs, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CSI)0000N/A
MediPharm Labs02023.00

MediPharm Labs has a consensus price target of C$1.53, suggesting a potential upside of 229.03%.

Summary

MediPharm Labs beats (CSI) on 2 of the 2 factors compared between the two stocks.

(CSI) (CNSX:CSI) and Khiron Life Sciences (CVE:KHRN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares (CSI) and Khiron Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CSI)N/AN/AN/A
Khiron Life SciencesN/AN/AN/A

Valuation and Earnings

This table compares (CSI) and Khiron Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CSI)N/AN/AN/AN/AN/A
Khiron Life SciencesC$8.01 million9.56C$-39,493,921.00C($0.26)-1.94

(CSI) has higher earnings, but lower revenue than Khiron Life Sciences.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for (CSI) and Khiron Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CSI)0000N/A
Khiron Life Sciences0000N/A

Khiron Life Sciences has a consensus price target of C$1.20, suggesting a potential upside of 135.29%.

Summary

Khiron Life Sciences beats (CSI) on 1 of the 1 factors compared between the two stocks.

(CSI) (CNSX:CSI) and Delta 9 Cannabis (TSE:DN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares (CSI) and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CSI)N/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for (CSI) and Delta 9 Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CSI)0000N/A
Delta 9 Cannabis00014.00

Delta 9 Cannabis has a consensus target price of C$1.10, suggesting a potential upside of 89.66%.

Valuation & Earnings

This table compares (CSI) and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CSI)N/AN/AN/AN/AN/A
Delta 9 CannabisC$52.05 million1.14C$-7,346,808.00C($0.07)-8.06

(CSI) has higher earnings, but lower revenue than Delta 9 Cannabis.

Summary

Delta 9 Cannabis beats (CSI) on 2 of the 2 factors compared between the two stocks.

Meta Growth (CVE:META) and (CSI) (CNSX:CSI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Meta Growth and (CSI)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96 million0.54$-50,412,840.00C($0.21)-0.66
(CSI)N/AN/AN/AN/AN/A

(CSI) has lower revenue, but higher earnings than Meta Growth.

Profitability

This table compares Meta Growth and (CSI)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta GrowthN/AN/AN/A
(CSI)N/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Meta Growth and (CSI), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth0000N/A
(CSI)0000N/A

Summary

Meta Growth beats (CSI) on 1 of the 1 factors compared between the two stocks.

pixel
Ad RSF MGMT
This Company Just Secured One Of The Biggest Retailers.
With products hitting nationwide Rite Aid stores, this company is about to get noticed!

(CSI) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RIV
RIV Capital
0.8$2.04flatC$270.11 millionC$15.44 million-2.69
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.28flatC$157.78 millionC$10,000.00-3.09Gap Down
LABS
MediPharm Labs
1.4$0.47flatC$119.95 millionC$36.01 million-0.97
KHRN
Khiron Life Sciences
0.9$0.51flatC$67.34 millionC$8.01 million-1.94Gap Down
DN
Delta 9 Cannabis
1.4$0.58flatC$59.18 millionC$52.05 million-8.06
META
Meta Growth
0.8$0.14flatC$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis
0.7$0.14flatC$36.44 millionC$17.36 million-0.53
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.